Use of VEGF antibody and VEGF receptor antagonist in preparation of pain-killing vaccine or medicament

Abstract

The invention discloses the novel use of a VEGF antibody and a VEGF receptor antagonist in the fields of pain-killing vaccines and pharmacy, namely the use of the VEGF antibody or the VEGF receptor antagonist in the preparation of an acute/chronic pain killing vaccine and a medicament for treating P2X3 and P2X2/3 purine receptor-mediated nerve system diseases. Through experiments it is observed that the VEGF antibody can inhibit the algetic behavior response; and by using immunohistochemistry, in-situ hybridization, RT-PCR, protein blotting and other techniques, it is observed that the VEGF antibody can inhibit the expression of mRNAs and proteins of the P2X2 and P2X3 receptors, VEGF and F1k-1/VEGFR2 of rat dorsal root ganglia of a model of neuropathic pain. Experiments prove that the pain killing mechanism of the VEGF antibody is that the pain is killed by neutralizing the VEGF or antagonist VEGF receptor to reduce pathologic pains and by blocking the pain information transmission of dorsal root neurons. The invention provides a new method for preventing and treating acute and chronic pains. Meanwhile, it is shown that the VEGF antibody can inhibit the expression of the P2X2 and P2X3 receptors, which is favorable for the use of the VEGF antibody and the VEGF receptor antagonist in the prevention and treatment of nerve system diseases related to the P2X2 and P2X3 receptors.

Description

technical field [0001] The present invention relates to the invention field of the use of analgesic drugs, in particular to anti-vascular endothelial growth factor (vascular endothelial growth factor, VEGF) antibodies and vascular endothelial growth factor receptor antagonists which can be used to prevent and treat pain in the preparation of acute / chronic pain (neuropathy) Pain) application in vaccines or medicines. Background technique [0002] Pain is a common symptom of most diseases, and it is an unpleasant feeling common to all human beings with great individual differences. Because pain causes great suffering to people, according to the second issue of 2001 "International Pain Society Newsletter" report: the 106th Congress of the United States passed a resolution, announcing that the ten years from January 1, 2001 will be "pain control and Decade of Pain Control and Research. This shows that countries attach importance to pain research. According to the pain time co...

AI Technical Summary

Problems solved by technology

There is no literature report on the relationship between VEGF and neuropathic pain, and there is no report that anti-VEGF antibodies or VEGF receptor antagonists directly have a

Images